Alprostadil in Maculopathy Study (AIMS)

Summary

Evaluation of efficacy of alprostadil (prostaglandin E1) for treatment of patients suffering from dry age-related macula degeneration

Timeline

Start

2006-07

Primary completion

2010-02

Completion

2010-02

Outcome

Missed primary endpoint

Stopped: “Interim Analysis: Optimization of study design required.”

registry analysis (superiority or other test); Alprostadil vs Placebo; p = 0.1220; Mean Difference (Final Values) 0.94 (95% CI -0.674 to 2.55); ANCOVA NCT00619229 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alprostadil	Unknown	60 ug	Intravenous

Indications